Iha Hidekatsu

イハヒデカツ | Iha Hidekatsu

Affiliation and department：

Research field (6)： Molecular biology , Immunology , Tumor biology , Virology , Laboratory animal science , Experimental pathology

Research keywords (4)：分子免疫学 , 分子腫瘍学 , 細胞生物学 , 分子生物学

Research theme for competitive and other funds (13)：

2021 - 2024 発症危険度を峻別する新規ATLバイオマーカーの同定と臨床検体における評価
2017 - 2021 ATLL及びB細胞性リンパ腫発症リスク評価・判定法の開発
2017 - 2019 Molecular and sero-epidemiologcal survey on the prevalence of human T-lymphotropic virus type 1 (HTLV-1), a causative agent of adult T-cell leukemia / lymphoma, in Sabah, Malaysia
2015 - 2018 Identification of ATLL-associated genes in Rapid ATLL model mouse
2016 - 2018 レクチンマイクロアレイを用いた食道癌の再発予測マーカーの開発

Show all

Papers (77)：

Haruka Sudo, Yasuhiro Tonoyama, Emi Ikebe, Hiroo Hasegawa, Hidekatsu Iha, Yo-Ichi Ishida. Proteomic analysis of adult T-cell leukemia/lymphoma: A biomarker identification strategy based on preparation and in-solution digestion methods of total proteins. Leukemia research. 2024. 138. 107454-107454
Tomonaga Ichikawa, Akira Suekane, Shingo Nakahata, Hidekatsu Iha, Kazuya Shimoda, Takashi Murakami, Kazuhiro Morishita. Inhibition of PRMT5/MEP50 Arginine Methyltransferase Activity Causes Cancer Vulnerability in NDRG2low Adult T-Cell Leukemia/Lymphoma. International journal of molecular sciences. 2024. 25. 5
Yu Wang, Shunsuke Shimosaki, Emi Ikebe, Hidekatsu Iha, Jun-ichi Yamamoto, Nichole Fife, Tomonaga Ichikawa, Mitsuo Hori, Masao Ogata, Yoshiyuki Tsukamoto, et al. IMiD/CELMoD-induced growth suppression of adult T-cell leukemia/lymphoma cells via cereblon through downregulation of target proteins and their downstream effectors. Frontiers in Oncology. 2024. 13
Yu Wang, Hidekatsu Iha. The Novel Link between Gene Expression Profiles of Adult T-Cell Leukemia/Lymphoma Patients' Peripheral Blood Lymphocytes and Ferroptosis Susceptibility. Genes. 2023. 14. 11
Naoki Osada, Jiro Kikuchi, Hidekatsu Iha, Hiroshi Yasui, Sho Ikeda, Naoto Takahashi, Yusuke Furukawa. c-FOS is an integral component of the IKZF1 transactivator complex and mediates lenalidomide resistance in multiple myeloma. Clinical and Translational Medicine. 2023. 13. 8

ｍore...

MISC (99)：

高橋美咲, 津山尚宏, 伊波英克, 坂井晃. IMiDs耐性骨髄腫細胞株によるトランスクリプトーム/プロテオーム解析を用いた新規治療標的分子探索. 日本血液学会学術集会. 2022. 84回. 1173-1173
伊波英克, 王宇, 下崎俊介, 池辺詠美, 山本淳一, ファイフ・ニコール, 市川朝永, 堀光雄, 緒方正男, 塚本善之, et al. IMiDs/CELMoDによるATL細胞の増殖抑制とその機序. 日本血液学会学術集会. 2022. 84回. 1215-1215
高橋美咲, 津山尚宏, 伊波英克, 坂井晃. IMiDs耐性骨髄腫細胞株によるトランスクリプトーム/プロテオーム解析を用いた新規治療標的分子探索. 日本血液学会学術集会. 2022. 84回. 1173-1173
伊波英克, 王宇, 下崎俊介, 池辺詠美, 山本淳一, ファイフ・ニコール, 市川朝永, 堀光雄, 緒方正男, 塚本善之, et al. IMiDs/CELMoDによるATL細胞の増殖抑制とその機序. 日本血液学会学術集会. 2022. 84回. 1215-1215
須藤遥, 殿山泰弘, 櫻田富美子, 池辺詠美, 伊波英克, 石田洋一, 石田洋一. ATL proteomics: Biomarker identification by total cell protein analysis. 日本薬学会年会要旨集(Web). 2022. 142年会. 27PO1-82

ｍore...

Patents (7)：

非ホジキンリンパ腫発症のリスク判定補助方法
Methods for determining drug efficacy for treatment of cancers using ratios of cereblon associated proteins.
Methods for determining;drug efficacy for;treatment of cancer using;ratios of cereblon;associated proteins
成人T細胞白血病/リンパ腫の発症抑制剤の有効成分をスクリーニングする方法
糖質プロファイリングによる血液腫瘍診断方法

ｍore...

Books (2)：

T-Cell Leukemia - Characteristics, Treatment and Prevention
INTECH 2013
HTLV-1と疾患
文光堂 2007

Committee career (3)：

2023/07 - 現在 Frontiers in Microbiology (Virology) Associate Editor
2014/08 - 現在日本HTLV-1学会評議員
2008/04 - 2012/07 大分TLO 理事

Awards (2)：

2003 - NIH recognized employee award
2002 - NIH recognized employee award

Association Membership(s) (9)：

American Society for Microbiology , THE JAPANESE ASSOCIATION FOR MOLECULAR TARGET THERAPY OF CANCER , THE JAPANESE CANCER ASSOCIATION , THE MOLECULAR BIOLOGY SOCIETY OF JAPAN , 日本HTLV-1学会 , JAPANESE SOCIETY FOR IMMUNOLOGY (JSI) , THE JAPANESE SOCIETY FOR VIROLOGY , THE JAPANESE SOCIETY FOR COMPLEMENTARY AND ALTERNATIVE MEDICINE , THE SOCIETY FOR BIOTECHNOLOGY, JAPAN

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page